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Title  
Non-Malignant Pleural Effusions (NMPE): a prospective study of 356 consecutive 
unselected patients.  
For CHEST Journal  
 
Background 
Pleural effusions secondary to a non-malignant aetiology can represent significant morbidity and mortality. These non-malignant 
pleural effusions (NMPE) are common, with congestive heart failure (CHF) representing the leading cause.  Despite this, there is 
limited data on mortality risk and the factors which influence them. 
Methods 
We recruited 782 consecutive patients presenting to a pleural service, between 03/2008 and 03/2015, with an undiagnosed 
pleural effusion. Further analysis was conducted on the 356 patients with NMPE. Pleural biochemistry, cytology, thoracic USS and 
chest radiograph were performed.  Echocardiogram, CT scans, radiology-guided biopsy and medical thoracoscopy were 
undertaken as clinically indicated. Patients were followed-up for a minimum duration of 12 months with final diagnosis decided 
by independent review by 2 respiratory consultants.  
 
Results  
Of the 782 patients, 356(46%) were diagnosed with a NMPE.  These patients had a mean age of 68(SD17) with 69% of patients 
male. Cardiac, renal and liver failure patients had 1-year mortality rates of 50%, 46% and 25% respectively. Bilateral effusions (HR 
3.55 CI 2.22-5.68) and transudative effusions (HR 2.78 CI 1.81-4.28) were associated with a worse prognosis in patients with NMPE, 
with a 57% and 43% 1-year mortality respectively.   
 
Conclusions  
This is the largest prospectively collected series in patients with NMPE, demonstrating that those secondary to organ dysfunction 
have an extremely high 1-year mortality. In addition, the presence of bilateral and transudative effusions are an indicator of 
increased mortality. Clinicians should be aware of these poor prognostic features and guide management accordingly. 
 
Introduction  
1.5 million people develop pleural effusions each year in the United States1  with an estimated 1.1 to 1.3 million caused 
by a non-malignant aetiology1,2. Non-malignant pleural effusions (NMPE) are caused by either systemic factors, such 
as heart, liver or renal failure or local factors such as infection, pulmonary embolism, inflammatory pleuritis or thoracic 
surgery. Despite congestive heart failure (CHF) representing the leading cause of pleural effusions3  there is very limited 
data on the mortality rates in NMPE. The evidence that is available suggests a poor prognosis, with one case series 
demonstrating a median survival of 1 year in effusions secondary to CHF 4.  
The aim of this study was to determine the mortality rates in NMPE by undertaking a prospective observational trial 
that would evaluate baseline factors associated with increased mortality. 
Materials and Methods: 
We identified 782 consecutive patients in a prospective observational cohort study, presenting with a new 
undiagnosed pleural effusion, to a single UK institute, between 03/2008 and 03/2015. Patients were recruited as both 
inpatients and outpatients.   
Pleural and serum biochemistry, pleural cytology, thoracic ultrasound (USS) and a chest radiograph were performed 
on all patients.  Echocardiogram, computerised tomography (CT) scans, radiological-guided biopsy and medical 
thoracoscopy were undertaken as clinically indicated. Patients were followed-up for a minimum duration of 12 months 
or until death, with the final diagnosis decided by independent review by two respiratory consultants. Where more 
than one aetiology was felt to be responsible, the principal contributing factor was listed first. There was a high level 
(0.94 p<0.001) of inter-observer agreement, as calculated by kappa statistics. Patients were classified into diagnostic 
categories for analysis: malignant; CHF; liver failure; renal failure; pleural infection (empyema, complicated 
parapneumonic effusion, simple parapneumonic effusion, TB pleuritis); benign asbestos pleural effusion & diffuse 
pleural thickening (DPT); coronary artery bypass graft (CABG), pulmonary embolism, and other (including chylothorax, 
rheumatic, trauma and drug-induced). Effusions were defined as malignant if either the primary or secondary 
diagnoses included a malignant cause. 
Effusions were classified either as transudative or exudative by Lights criteria5 and either bilateral or unilateral based 
on PA chest radiograph appearance.  The effusions were categorised by cytology as either blood, macrophage, 
neutrophilic or lymphocytic predominant (>50%), mixed if no clear predominance in cytology and eosinophilic if >10% 
eosinophils. Eastern Cooperative Oncology Group Performance score (ECOG-PS)6 was recorded for 77.6% of patients.  
Survival data was calculated from date of study entry to date of death. Surviving patients were censored on 07/2016. 
The study protocol was approved by local ethical approval, South-West Bristol Research Ethics Committee (Ref 
08/H0102/11), in accordance with the Declaration of Helsinki. Study participants gave written informed consent. 
Statistics Analysis  
Descriptive statistics were used to summarise patient characteristics and clinical data. Means (±SD) were calculated 
for age and percentage values for subgroups. Multivariate proportional hazard ratios were calculated using Cox 
regression analysis for 6 and 12 month mortality for presence of bilateral pleural effusion (compared to unilateral), 
transudative effusions (compared to exudative), and the following aetiologies (compared to malignant pleural effusion 
cohort): CHF, liver failure, pleural infection, renal failure, BAPE/DPT, CABG, PE, and other. Kaplan-Meier plots for 
survival probabilities were created for overall mortality and stratified for aetiologies, bilateral vs unilateral effusions 
and transudative for exudative effusions. All statistical analyses were performed using IBM SPSS statistics version 23.0 




Data was obtained for a total of 782 patients, with 774 included in analysis.  Eight participants were excluded for 
multiple reasons, including no diagnosis reached at 12 months and withdrawal of consent. Further analysis was 
conducted on the 356 (46%) patients with NMPE (see Figure 1) 
 
 
The baseline characteristics for NMPE cohort are presented in table 1, with characteristics by aetiology presented in 
table 2.  The majority of NMPE were exudative (73%), unilateral (88%) with pleural infection being the commonest 
aetiology (40.6 %). Nearly a quarter (23.6%) of the NMPEs were felt to have more than one identifiable cause. 
Mortality rates and multivariate predictors of mortality in NMPE cohort are displayed in table 3, with hazards ratio of 
bilateral effusion compared to unilateral, transudative effusion compared to exudates and aetiology compared to 
malignancy.  There were high 1-year mortality rates in patients with congestive heart (50%), renal (46%) and liver 
failure (25%). Thirty day mortality was low, at 9% for CHF and no deaths in the liver and renal failure cohort. Malignant 
pleural effusions had the highest mortality at 49% and 70% at 6 and 12 months respectively. In patients with NMPE, 
bilateral and transudative effusions were associated with a significantly worse prognosis with HR 3.55(2.22-5.68) and 
2.78(1.81-4.28) when compared to unilateral and exudative effusions respectively. A serosanguinous effusion was 





Non-malignant pleural effusions are not a benign process, and represent a significant mortality risk. This paper 
demonstrates that patients with effusions secondary to organ failure (heart, liver, and kidney) are at significantly 
higher risk than those related to a local disease process, whether that be infection or inflammation. Correspondingly, 
the transudative, bilateral effusions that often accompany organ failure are independently associated with a worse 
prognosis. This supports the findings of an earlier paper demonstrating high mortality rates in CHF, liver and renal 
failure4.  These mortality rates are not dissimilar to that seen in some malignant disease. Effusions refractory to medical 
therapy and repeated aspiration may require more definitive management strategies. This may involve disease specific 
procedures, including transjugular intrahepatic portosystemic shunt (TIPS) procedure or liver transplantation in liver 
disease, or pleural interventions including pleurodesis or indwelling pleural catheter placement. 
 
CHF is the commonest cause of pleural effusions, with as many as  87% of patients with decompensated heart failure 
requiring diuresis having  pleural effusions7. The documented 1-year mortality risk for patients with CHF is broad, 
ranging from 11-30% 8-14, with multiple studies examining the risk factors associated with mortality 10,15-19 
(echocardiogram criteria, NYHA score, age, male gender, blood pressure, CRP, renal dysfunction and biomarkers15 to 
name a few). There has been little work performed investigating whether the presence of an effusion effects prognosis, 
with the studies that have examined this either looking at incidental effusions found on transthoracic 
echocardiogram20 or small effusion that didn’t required thoracentesis21.  The one year-mortality rate for patients with 
an effusion secondary to heart failure in our cohort was found to be 50%, similar to the 1- year mortality rate (46%) of 
patients with acute decompensated heart failure admitted to intensive and coronary care units22 and significantly 
more than the 1 year mortality for outpatients with NYHA class IV CHF (28%)8  
Hepatic hydrothorax is a complication of liver cirrhosis in which hydrostatic imbalances result in fluid accumulation 
within the pleural space23 and occurs in 6-10% of patient with advanced liver cirrhosis24. The initial management is a 
low-salt diet and diuretics, although 20% of patients are refractory to this25, and may require a transjugular 
intrahepatic portosystemic shunt (TIPS) procedure or  liver transplantation. In our cohort hepatic hydrothorax was a 
predictor of significant mortality, with a quarter of patients dying within a year. This is higher than patients  with 
chronic alcoholic liver disease (16.4%)26 and equivalent to a high MELD (Model For End-Stage Liver Disease) score of 
20-2926 that would be an indication for liver transplant.   
A fifth of patients on long-term haemodialysis will have a pleural effusion 27, usually as a result of hypervolaemia, 
though heart failure, parapneumonic effusion and uraemic pleuritis may be responsible 27. 1.6-10% of patients on 
peritoneal dialysis (PD) will also develop a PD-related effusion28, which can occur from pleuro-peritoneal 
communication via a porous diaphragm28,29. A study looking at mortality in patients with effusion secondary to PD 
demonstrated a wide range between the different cohorts, with the worse outcomes amongst those with fluid 
overload, with a median survival of around a year30.  The renal cohort in our study had a high 1-year mortality rate 
(46%)  which is  triple the one-year mortality (15.6%) of patients on dialysis 31. The increased hazard ratio associated 
with renal failure do not, however, reach significance, presumably due to low numbers in the cohort.  
Infections of the pleural space are common and associated with high mortality32. In our cohort, the 1-year mortality 
(19%) was similar to documented mortality rates for pleural infection 32-34.  The mortality rate in patients with pleural 
effusions secondary to pulmonary embolism or post CABG were slightly higher than would be expected35,36,  however 
the numbers involved were low (5 and 6 patients, respectively) and the associated increased hazard ratios do not 
reach statistical significance. Therefore we cannot conclude whether the presence of an effusion is an adverse 
prognostic feature in these conditions. 
In this study, the presence of a transudate or bilateral effusions were independently associated with increased hazard 
ratios and higher mortality rates, with 43% and 18% 1-year mortality in transudative and exudative effusions 
respectively and a 57% and 20% 1-year mortality rates in bilateral vs unilateral effusion. This supports the findings that 
pleural effusions secondary to organ (heart, renal and liver) dysfunction, as opposed to an exudative effusion 
secondary to localised inflammation is an indicator of poorer prognosis. 
To our knowledge this is the largest prospective study to date examining the mortality rates in NMPE. It included 
approximately equal inpatient and outpatient numbers and involved patients managed by a range of specialities. All 
patients presenting with an undiagnosed pleural effusion were eligible aside from those excluded if they could not 
give informed consent, declined to participate in the trial or were pregnant or lactating. The findings are consistent 
with a previous study demonstrating high mortality rates in patients with CHF and bilateral effusions4. 
A limitation of this study is that it was performed at a single centre. All these patients required pleural aspiration, 
either for diagnostic or therapeutic purposes. A diagnostic aspirate would not usually be indicated for an effusion with 
a high pre-test probability of cardiac aetiology and a low probability for an alternate cause. Hence it is likely that the 
CHF effusions aspirated were either refractory to medical management or there was level of concern in the treating 
physician that warranted an invasive investigation. This is the likely explanation for pleural infection representing the 
commonest cause of NMPE in our cohort, as opposed to CHF worldwide3. We cannot comment on the mortality rate 
amongst patients that did not require a pleural procedure, and it is likely that requiring an aspiration in NMPE is an 
indicator of disease severity in itself.  
 
Conclusion  
This is the largest prospectively collected series in patients with NMPE to date, demonstrating that pleural effusions 
secondary to organ dysfunction, in particularly cardiac, have an extremely high 1-year mortality and the presence of 
an effusion requiring aspiration is a marker of severe disease and poor prognosis. In addition, the presence of bilateral 
and transudative effusions are an indicator of increased mortality. Clinicians and patients should be aware of this poor 
prognostic features and guide management accordingly. 
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